Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.

In preclinical studies, a B-Raf inhibitor called WYE-130600 caused dose-related skin effects in dogs and rats, suggesting potential similar responses might occur in humans.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This study found that locally injected zalutumumab in healthy volunteers induced a papulopustular rash similar to systemic EGFR inhibitors, and that IL-8 inhibition reduced this dermatological side effect.

In this study, the researchers identified that perturbing both AKT1 and MDM2 significantly reduces epithelial-mesenchymal transition in melanoma, proposing Cialis and Finasteride as potential therapeutic candidates with favorable properties for managing aggressive melanoma.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This study found that the epirubicin-docetaxel chemotherapy regimen for metastatic breast cancer resulted in a clinical response in 55% of patients, with maintained global quality of life despite some impairments.

In this study, patients with specific skin and scalp conditions, including eczematous lesions, showed significant improvement after two weeks of oral tofacitinib treatment, as evidenced by changes in the trunk lesions.

In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

This study found that P144 (Disitertide) significantly reduced collagen deposition and improved muscle organization in a rabbit model of post-radiotherapy fibrosis, suggesting potential antifibrotic effects.

This study observed that JAK inhibitors were safe and effective for patients with moderate-to-severe alopecia areata and comorbid latent hepatitis B or stable tuberculosis, with careful monitoring and selective prophylaxis.

Baricitinib helps regrow hair in teens with severe alopecia areata.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

This study found that the administration of the mutant BRAF inhibitor dabrafenib in patients with metastatic melanoma was associated with various skin lesions, including keratinocytic proliferation that sometimes showed low-grade malignancy features.

This study describes the positive effects of the JAK inhibitor ruxolitinib in treating autoimmune manifestations in three patients with autoimmune polyendocrine syndrome type-1 over a period of at least 30 months, with excellent tolerance and no adverse events observed.

This study concluded that etretinate showed only moderate effects in treating lichen sclerosus and localized scleroderma, with some patients experiencing clearing but others having no resolution or lesion progression.

Ritlecitinib works well and is safe for treating alopecia areata.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

This study found that CI-1033 caused skin lesions in rats that resemble effects seen in humans receiving EGF receptor inhibitors, suggesting this animal model can help explore the mechanisms behind this cutaneous toxicity.